Ability Pharma
-
DATABASE (12)
-
ARTICLES (111)
Founded in 1994, Fosun Pharma covers all key sectors of the pharmaceutical and healthcare industrial chain. It has been aggressively expanding globally, conducting investment and M&As in healthcare industries.
Founded in 1994, Fosun Pharma covers all key sectors of the pharmaceutical and healthcare industrial chain. It has been aggressively expanding globally, conducting investment and M&As in healthcare industries.
A spinoff from Chinese investment bank China International Capital Corp, CDH has its roots in private equity. It started in 2002, raising its first fund of US$102 million. As of end-2015, it had over US$15 billion in assets under management, spanning private equity, public equities, real estate and more. It has invested in more than 150 companies, including WH Group, Belle International, Mengniu Dairy, Qihoo 360 and Luye Pharma; and has offices in Beijing, Hong Kong, Shanghai, Shenzhen, Singapore and Jakarta.
A spinoff from Chinese investment bank China International Capital Corp, CDH has its roots in private equity. It started in 2002, raising its first fund of US$102 million. As of end-2015, it had over US$15 billion in assets under management, spanning private equity, public equities, real estate and more. It has invested in more than 150 companies, including WH Group, Belle International, Mengniu Dairy, Qihoo 360 and Luye Pharma; and has offices in Beijing, Hong Kong, Shanghai, Shenzhen, Singapore and Jakarta.
Passion Capital is an early stage venture capital firm that has been involved in several large European technology exits, such as QXL/Tradus, Ricardo.de and Last.fm. The partners include Robert Dighero, Eileen Burbidge and Stefan Glaenzer who believe that the passion and ability of the founders are critical keys to success. Passion Capital has a hub for activities in White Bear Yard in London and invests in digital media and technology companies.
Passion Capital is an early stage venture capital firm that has been involved in several large European technology exits, such as QXL/Tradus, Ricardo.de and Last.fm. The partners include Robert Dighero, Eileen Burbidge and Stefan Glaenzer who believe that the passion and ability of the founders are critical keys to success. Passion Capital has a hub for activities in White Bear Yard in London and invests in digital media and technology companies.
Besides helping medics around the world to diagnose Covid-19 infections, WeDoctor has launched China's first Internet hospitals to provide quality healthcare on-demand.
Besides helping medics around the world to diagnose Covid-19 infections, WeDoctor has launched China's first Internet hospitals to provide quality healthcare on-demand.
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
The first on-demand mobility service in francophone West Africa, Teliman is boosting transportation links and drivers’ economic development, especially for women; eyes expanding to logistics.
The first on-demand mobility service in francophone West Africa, Teliman is boosting transportation links and drivers’ economic development, especially for women; eyes expanding to logistics.
Plant protein material for commercial use to replace single-use plastics, with the performance of synthetic polymers, but 100% biodegradable in the natural environment.
Plant protein material for commercial use to replace single-use plastics, with the performance of synthetic polymers, but 100% biodegradable in the natural environment.
Used by major Hollywood film studios, including in Star Wars and Frozen movies, Sound Particles' software apes CGI technology to create complex, realistic 3D sounds.
Used by major Hollywood film studios, including in Star Wars and Frozen movies, Sound Particles' software apes CGI technology to create complex, realistic 3D sounds.
Founded in 2013 in Singapore, VVNP is a future-food solutions-orientated investor with a special interest in science-based companies that have the ability to scale global solutions, especially within Asia. It invests from seed stage to Series C level. Typical investments range from $300,000 to $3m and the investor has launched two funds to date. The first raised $40m and invested in seven companies globally, while the second was created in 2020, targeting $150m in total investment.The VC’s most recent investments include a €271,000 pre-seed investment round in Dutch poultry animal welfare biotech In Ovo in March 2021, and leading the as-yet-uncompleted 6m Swiss franc (approximately $6.56m) seed round in Swiss biotech SwissDeCode in January 2021 – a company that applies DNA testing to food traceability.
Founded in 2013 in Singapore, VVNP is a future-food solutions-orientated investor with a special interest in science-based companies that have the ability to scale global solutions, especially within Asia. It invests from seed stage to Series C level. Typical investments range from $300,000 to $3m and the investor has launched two funds to date. The first raised $40m and invested in seven companies globally, while the second was created in 2020, targeting $150m in total investment.The VC’s most recent investments include a €271,000 pre-seed investment round in Dutch poultry animal welfare biotech In Ovo in March 2021, and leading the as-yet-uncompleted 6m Swiss franc (approximately $6.56m) seed round in Swiss biotech SwissDeCode in January 2021 – a company that applies DNA testing to food traceability.
CEO and co-founder of String Bio
Ezhil Subbian studied industrial biotechnology at Anna University in India. She then went to the US to complete two PhDs in biochemistry, biophysics and molecular biology at the Oregon Health & Science University and from Rutgers, the State University of New Jersey-New Brunswick. She was a research assistant at both universities.While in the US, she was also a research scientist at Gevo Inc and at Vollum Institute. In 2008, she became a scientist and technical lead at pharma Codexis in California. In 2011, she worked at San Francisco-based Kumar Investments as an entrepreneur and biotech consultant.In 2012, she founded biotech startup String Inc while on a nine-month Startup Leadership Program in Silicon Valley. In June 2013, she and husband returned to India and formed a new company String Bio to continue working on the alternative protein powder project for animal feed production.
Ezhil Subbian studied industrial biotechnology at Anna University in India. She then went to the US to complete two PhDs in biochemistry, biophysics and molecular biology at the Oregon Health & Science University and from Rutgers, the State University of New Jersey-New Brunswick. She was a research assistant at both universities.While in the US, she was also a research scientist at Gevo Inc and at Vollum Institute. In 2008, she became a scientist and technical lead at pharma Codexis in California. In 2011, she worked at San Francisco-based Kumar Investments as an entrepreneur and biotech consultant.In 2012, she founded biotech startup String Inc while on a nine-month Startup Leadership Program in Silicon Valley. In June 2013, she and husband returned to India and formed a new company String Bio to continue working on the alternative protein powder project for animal feed production.
Chief Growth Officer and co-founder of Kobo360
After graduating in business administration at the University of Michigan-Dearborn in 2013, Ife Oyedele II stayed on at the university to obtain a master’s in information technology in 2016.While studying in Michigan, Oyedele met up with Obi Ozor and the two friends started an e-commerce venture to sell diapers and baby soap from the US to customers in Nigeria. Ozor later moved to Philadelphia to continue his studies at Wharton School.Still at university, he gained work experience in business intelligence at Michigan consultancy firm CFI Group for about three years. He has also conducted some research for pharma group iLabs and completed stints in business analysis and quality assurance at various companies. In May 2014, he joined General Fuels company in Detroit and worked as a business manager for almost two years.In 2016, Ozor and Oyedele co-founded Uber-style logistics platform Kobo360 in Nigeria. Oyedele was CTO at Kobo360 until 2020 when he became the company’s Chief Growth Officer.
After graduating in business administration at the University of Michigan-Dearborn in 2013, Ife Oyedele II stayed on at the university to obtain a master’s in information technology in 2016.While studying in Michigan, Oyedele met up with Obi Ozor and the two friends started an e-commerce venture to sell diapers and baby soap from the US to customers in Nigeria. Ozor later moved to Philadelphia to continue his studies at Wharton School.Still at university, he gained work experience in business intelligence at Michigan consultancy firm CFI Group for about three years. He has also conducted some research for pharma group iLabs and completed stints in business analysis and quality assurance at various companies. In May 2014, he joined General Fuels company in Detroit and worked as a business manager for almost two years.In 2016, Ozor and Oyedele co-founded Uber-style logistics platform Kobo360 in Nigeria. Oyedele was CTO at Kobo360 until 2020 when he became the company’s Chief Growth Officer.
Advisor, board member, co-founder of NovoNutrients
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO. Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne. Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations. Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
Brian Sefton has been co-founder, a board member and a part-time advisor at NovoNutrients, a San Francisco-based biotech manufacturer of alt-protein produced from fermentation and CO2 since it was founded in 2017. In 2009, he co-founded research entity Oakbio, from which NovoNutrients evolved, and was its President and CTO. Sefton was CTO and President at NovoNutrients and also co-CEO and Chief Scientist at Oakbio until 2021 when he became the CEO at San Francisco-based fermentation commercialization startup Sincarne. Between 2005 and 2011, Sefton was also CEO at pharma research company Pharmadyn, working on drugs development for Alzheimer's Disease, and, for three of those years, was also Managing Partner of Stratsyn, a consultancy specializing in creation, development, management and fund raising for not-for-profit organizations. Sefton’s earlier posts include: directing nanotechnology commercialization and investment company Nanosig for three years, CEO of Silicon Valley’s Fastlane, a high-profile pioneer in real-time network traffic and security analysis for six years; and, simultaneously, being CEO at Bluebox Communications, developing high-end network security applications and appliances for Fortune 500 companies and the US government.Sefton holds an MBA from Santa Clara University in California and a bachelor’s degree in biochemistry from the University of California, Berkeley
Southeast Asian startups to keep riding digitalization, IPO boom, investors say
O2O business models and growing interest in ESG are also key themes, as regional startups gain $4.4bn of funding in first half of 2021
Indonesia 2021 outlook: VCs "cautiously optimistic" on Southeast Asia's largest country
Investors expect Indonesian startups to regain their growth opportunities when the economy reopens with the Covid-19 vaccine rollout, even as some online living and working habits have stuck
Autodrive Solutions: Making driverless vehicles safer with high-precision positioning tech
A Spanish university's research on sophisticated weapons detection technology is being used to prevent accidents in the mobility and transport sectors
Animal AgTech Innovation Summit 2021: Future of aquaculture in the US
With the US Importing over 85% of its seafood, industry experts examine how and why the country should develop a sustainable aquaculture industry
SWITCH Singapore 2021: Tapping the $1tn sustainability market in Southeast Asia
Falling costs and simplified deployment of sustainability solutions will help boost adoption, especially in underprivileged communities
Tonic App: Just the tonic for overburdened doctors
CEO Daniela Seixas and COO Gonçalo Vilaça discussed Tonic App, their free solution for streamlining administrative tasks in the medical sector
Sorry, we couldn’t find any matches for“Ability Pharma”.
POPULAR DATABASE
